Recombinant multi-species FIP1L1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FIP1L1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]
The Alternative Names of target: 1300019H17Rik,FIP1,FIP1-like 1 protein,FIP1L1,Factor interacting with PAP,Fip1l1,Pre-mRNA 3'-end-processing factor FIP1,Rearranged in hypereosinophilia,Rhe,Rje,hFip1
Go
to FIP1L1 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP12555-Ag-1/ GM-Tg-hg-IP12555-Ag-2 | Human FIP1L1 protein | Human |
| GM-Tg-rg-IP12555-Ag-1/ GM-Tg-rg-IP12555-Ag-2 | Rat FIP1L1 protein | Rat |
| GM-Tg-mg-IP12555-Ag-1/ GM-Tg-mg-IP12555-Ag-2 | Mouse FIP1L1 protein | Mouse |
| GM-Tg-cynog-IP12555-Ag-1/ GM-Tg-cynog-IP12555-Ag-2 | Cynomolgus/Rhesus macaque FIP1L1 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP12555-Ag-1/ GM-Tg-felg-IP12555-Ag-2 | Feline FIP1L1 protein | Feline |
| GM-Tg-cang-IP12555-Ag-1/ GM-Tg-cang-IP12555-Ag-2 | Canine FIP1L1 protein | Canine |
| GM-Tg-bovg-IP12555-Ag-1/ GM-Tg-bovg-IP12555-Ag-2 | Bovine FIP1L1 protein | Bovine |
| GM-Tg-equg-IP12555-Ag-1/ GM-Tg-equg-IP12555-Ag-2 | Equine FIP1L1 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-IP12555-Ag-1/ GM-Tg-hg-IP12555-Ag-2;
GM-Tg-rg-IP12555-Ag-1/ GM-Tg-rg-IP12555-Ag-2;
GM-Tg-mg-IP12555-Ag-1/ GM-Tg-mg-IP12555-Ag-2; GM-Tg-cynog-IP12555-Ag-1/ GM-Tg-cynog-IP12555-Ag-2; GM-Tg-felg-IP12555-Ag-1/ GM-Tg-felg-IP12555-Ag-2; GM-Tg-cang-IP12555-Ag-1/ GM-Tg-cang-IP12555-Ag-2; GM-Tg-bovg-IP12555-Ag-1/ GM-Tg-bovg-IP12555-Ag-2; GM-Tg-equg-IP12555-Ag-1/ GM-Tg-equg-IP12555-Ag-2 |
| Products Name | FIP1L1 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | FIP1L1 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FIP1L1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.